AGC Pharma Chemicals Europe (APCE) (A): A cultural transformation journey
This case study explores the transformation of a pharmaceutical production site in Malgrat de Mar (Barcelona) that was acquired by AGC from Boehringer Ingelheim (BI) in 2019. The goal was to turn the company into a competitive contract development and manufacturing organization (CDMO). Originally focused on stable, large-scale manufacturing for a single customer, the site required significant changes in technical capabilities, organizational culture, and business model.
AGC, a Japanese multinational with roots in the glass and chemical industries, started expanding into life sciences as part of its diversification strategy. To lead the transformation, the company appointed Hiro Kadokura, a seasoned executive with experience at both AGC and global pharmaceutical companies. His mission included integrating the site into AGC’s global network, developing new capabilities such as R&D, business development, and project management, and driving a profound cultural shift.
The case highlights cultural challenges arising from the intersection of AGC’s Japanese management style, the mindset of the Spanish workforce, and BI’s legacy of German structure and precision. A small group of internationally experienced Japanese expats and a mixed local–Japanese leadership team helped bridge these cultural gaps. With support from external consultants, APCE launched a cultural transformation process to move from a passive, compliance-driven environment to a more constructive, customer-focused, and agile organization.
Throughout the transformation, APCE faced critical tensions: balancing quality with flexibility, cost with value, and short-term delivery with long-term sustainability. However, with strategic investment, leadership development, and a clear cultural vision, the company made significant progress in repositioning itself as a credible CDMO partner in Europe. This case offers valuable insights into global leadership, cross-cultural integration, and the execution of complex organizational change in a highly regulated and competitive industry. It is especially relevant for those interested in transformation in international, multicultural settings.
What material is included in this case:
Description
This case study explores the transformation of a pharmaceutical production site in Malgrat de Mar (Barcelona) that was acquired by AGC from Boehringer Ingelheim (BI) in 2019. The goal was to turn the company into a competitive contract development and manufacturing organization (CDMO). Originally focused on stable, large-scale manufacturing for a single customer, the site required significant changes in technical capabilities, organizational culture, and business model.
AGC, a Japanese multinational with roots in the glass and chemical industries, started expanding into life sciences as part of its diversification strategy. To lead the transformation, the company appointed Hiro Kadokura, a seasoned executive with experience at both AGC and global pharmaceutical companies. His mission included integrating the site into AGC’s global network, developing new capabilities such as R&D, business development, and project management, and driving a profound cultural shift.
The case highlights cultural challenges arising from the intersection of AGC’s Japanese management style, the mindset of the Spanish workforce, and BI’s legacy of German structure and precision. A small group of internationally experienced Japanese expats and a mixed local–Japanese leadership team helped bridge these cultural gaps. With support from external consultants, APCE launched a cultural transformation process to move from a passive, compliance-driven environment to a more constructive, customer-focused, and agile organization.
Throughout the transformation, APCE faced critical tensions: balancing quality with flexibility, cost with value, and short-term delivery with long-term sustainability. However, with strategic investment, leadership development, and a clear cultural vision, the company made significant progress in repositioning itself as a credible CDMO partner in Europe. This case offers valuable insights into global leadership, cross-cultural integration, and the execution of complex organizational change in a highly regulated and competitive industry. It is especially relevant for those interested in transformation in international, multicultural settings.
Learning Objective
This case enables students to explore the key challenges and leadership strategies involved in the post-acquisition transformation of a pharmaceutical manufacturing site. The main learning objectives are as follows:
- Cultural Integration in Cross-Border M&A: Gain an understanding of the complexities of integrating diverse national and organizational cultures following a cross-border acquisition and examine the role of leadership in building trust, shared values, and collaborative practices across cultures.
- Strategic Vision and Organizational Transformation: Analyze how AGC’s long-term strategic vision in life sciences is translated into concrete organizational changes, including the development of new structures, capabilities, and mindsets necessary to shift from a traditional manufacturing model to a competitive CDMO business.
- Managing Multilayered Cultural Tensions: Reflect on the subtle and often conflicting cultural layers—national, corporate, professional, and legacy—that influence behaviors and decision-making in multinational settings and evaluate strategies for navigating and reconciling these tensions over time.
Leave your rating
"AGC Pharma Chemicals Europe (APCE) (A): A cultural transformation journey"
Register for free with IESE Publishing and enjoy all the advantages
What type of account do you want to create?
Choose account type
Professors
Academic Institutions
Companies
Individuals